Back to Search
Start Over
Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
- Source :
-
Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 175-183. Date of Electronic Publication: 2023 Oct 05. - Publication Year :
- 2024
-
Abstract
- Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUV <subscript>max</subscript> ], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (ΔSUV <subscript>max</subscript> , ΔTMTV and ΔTLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4-5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUV <subscript>max</subscript> , TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among ΔSUV <subscript>max</subscript> , ΔTMTV and ΔTLG, only a ΔSUV <subscript>max</subscript> ≥ 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11-0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (ΔSUV <subscript>max</subscript> ≥ 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the ΔSUV <subscript>max</subscript> to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.<br /> (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Subjects :
- Humans
Adult
Retrospective Studies
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Fluorodeoxyglucose F18
Bleomycin
Dacarbazine
Doxorubicin
Vinblastine
Prognosis
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Hodgkin Disease diagnostic imaging
Hodgkin Disease drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1432-0584
- Volume :
- 103
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Annals of hematology
- Publication Type :
- Academic Journal
- Accession number :
- 37796339
- Full Text :
- https://doi.org/10.1007/s00277-023-05461-6